

115. The method of claim 89, wherein the target site is adjacent to an RNA polymerase pause site downstream of a transcription initiation site of the endogenous cellular gene.

116. The method of claim 89, wherein the zinc finger protein comprises an SP-1 backbone.

117. The method of claim 116, wherein the zinc finger protein comprises a regulatory domain and is humanized. --

*A1  
cont'd  
ADD C17*

REMARKS

1. *Status of the claims*

New claims reciting nucleic acids encoding zinc finger proteins have been added, which correspond to the originally filed claims. These claims add no new matter.


Independent claim 89 recites a method of activating expression of an endogenous cellular gene, by administering a nucleic acid encoding a zinc finger protein. Claim 89 corresponds to original claim 1 rewritten to incorporate the nucleic acid element of original claim 19. New claims 89-125 correspond to original claims 1-30.

Independent claim 126 recites a method of inhibiting expression of an endogenous cellular gene, by administering a nucleic acid encoding a zinc finger protein. Claim 126 corresponds to original claim 31 rewritten to incorporate the nucleic acid element of original claim 49. New claims 126-146 correspond to original claims 31-60.

CONCLUSION

If the Examiner has any questions regarding Applicants' preliminary amendment, or if the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (415)576-0200.

Respectfully submitted,



Annette S. Parent  
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200 / Fax: (415) 576-0300  
SF 1155835 v1

2020 RELEASE UNDER E.O. 14176